Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Ingrid Mayer

10 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Treatment

VICCBRE1562

03/15/2016

SOLAR-1: A Phase III Randomized Double-Blind, Placebo Controlled Study of Alpelisib in combination with Fulvestrant for Men and Postmenopausal Women with Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer which Progressed on or After Aromatase Inhibitor Treatment

Treatment

VICCBRE1462

03/08/2016

A Phase I Dose Escalation Study of POL6326 with Eribulin in Patients with Relapsed Metastatic Breast Cancer

Treatment

VICCBRE1546

12/01/2015

The Impact of HER2 Heterogeneity on the Treatment of Early- Stage HER2-Positive Breast Cancer: A Phase II Study of T- DM1 in Combination with Pertuzumab in the Preoperative Setting

Treatment

VICCBRE1480

03/31/2015

A Randomized, Multicenter, Open Label Study of MM-302 plus Trastuzumab vs. Chemotherapy of Physician's Choice plus Trastuzumab in Anthracycline Naive Patients with Locally Advanced/Metastatic HER2-Positive Breast Cancer

Treatment

VICCBRE1246

03/13/2015

Enhancing Efficacy of Chemotherapy in Triple-Negative/Basal-Like Breast Cancers by Targeting Macrophages: A Phase Ib/II Study of PLX3397 and Eribulin in Patients with Metastatic Breast Cancer

Treatment

VICCMD1403

06/02/2014

An Open Label, Phase II Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification

Treatment

VICCBRE1391

04/24/2014

A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib versus Physician's Choice in Previously-Treated, HER2-Negative, Germline BRCA Mutation-Positive Breast Cancer Patients

Treatment

VICCBREP1363

03/21/2014

A Phase Ib/II, Multicenter, Study of the Combination of LEE011 and BYL719 with Letrozole in Adult Patients with Advanced ER+ Breast Cancer

Treatment

VICCBREP12116

03/25/2013

An Open-Label, Phase IA/IB/IIA Study of GDC-810 Single Agent or in Combination With Palbociclib and/or an LHRH Agonist in Women with Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Treatment

VICCPHI1248

10/12/2012

An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC0032 in Patients with Locally Advanced or Metastatic Solid Tumors and in Combination with Endocrine Therapy in Patients with Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer